engleski

Peroxisome proliferator-activated receptor gamma (PPARG) gene polymorphism in coronary artery disease patients and myocardial infarction survivors

Background. Proliferator-activated receptor gamma (PPARG) regulates adipocytes differentiation, glucose homeostasis and long-term lipid storage. The detection of PPARG in lesion macrophages, coupled with its identification as the molecular target of antidiabetic agents, has raised significant interest in the potential role of this receptor in coronary artery disease (CAD) and myocardial infarction (MI). Methods. A new fluorescence resonance energy transfer (FRET) genotyping assay for Pro12Ala polymorphism in PPARG gene was developed and used to genotype subjects with or without angiographically documented CAD and MI survivors. Serum glucose and lipid parameters were measured by standard enzymatic methods. Results. Genotype frequencies were in Hardy-Weinberg equilibrium. Absolute frequencies of PPARG Pro12Ala gene variants did not differ significantly between CAD+ and CAD- subjects. Pro/Pro, Pro/Ala and Ala/Ala genotypes were 491, 174 and 14 in CAD+ group, and 241, 70 and 4 in CAD- group, respectively. However, they differed significantly between subjects with (MI+) and without (MI-) history of MI. Pro/Pro, Pro/Ala and Ala/Ala genotypes were 235, 103 and 5 in MI+ group, and 497, 140 and 13 in MI- group, respectively. In a logistic regression, assuming the recessive mode of inheritance and Pro/Pro as a reference genotype, odds ratio for MI after correction for gender was 1.52 (95% confidence interval 1.13 to 2.03), p=0.0055. Serum levels of glucose and lipid parameters did not differ significantly between the studied groups. Conclusions. PPARG gene variants may confer increased risk for MI. Higher frequency of rare 12Ala allele in MI survivors indicates a protective role for Pro12 allele.

Proliferator-activated receptor gamma (PPARG); PPARG gene; coronary artery disease; myocardial infarction

nije evidentirano